LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

No False Positives with New Enterovirus D68 PCR-Based Assay

By LabMedica International staff writers
Posted on 16 Aug 2015
Image: Electron micrograph of a thin section of EV-D68, showing the numerous, spherical viral particles (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
Image: Electron micrograph of a thin section of EV-D68, showing the numerous, spherical viral particles (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
A newly developed PCR-based assay specifically detects current variants of Enterovirus D68 with no false positive reactions with other enteroviruses or with rhinoviruses.

Investigators at Washington University School of Medicine (St. Louis, MO, USA) used an Applied Biosystems (Foster City, CA, USA) 7500 real-time PCR system to develop and evaluate a real-time reverse transcriptase PCR (RT-PCR) assay for the detection of human Enterovirus D68 (EV-D68) in clinical specimens. This assay was developed in response to the unprecedented 2014 nationwide EV-D68 outbreak in the United States associated with severe respiratory illness.

The investigators mapped the genome sequence of the EV-D68 virus circulating in St. Louis (MO, USA). This sequence, along with other GenBank sequences from past EV-D68 occurrences, was used to computationally select a region of EV-D68 appropriate for targeting in a strain-specific RT-PCR assay. The RT-PCR assay amplified a segment of the VP1 gene, with an analytic limit of detection of four copies per reaction, and it was more sensitive than commercially available assays that detect enteroviruses and rhinoviruses without distinguishing between the two, including three multiplex respiratory panels approved for clinical use by the [US] Food and Drug Administration. The new assay did not detect any other enteroviruses or rhinoviruses tested and did detect divergent strains of EV-D68,

"Commercial tests for respiratory viral infections typically do not distinguish between rhinoviruses, which cause the common cold, and enteroviruses, and within each of those groups there are many different types," said senior author Dr. Gregory A. Storch, professor of pediatrics at Washington University School of Medicine. "Having a tool to identify which cases of respiratory illness are actually EV-D68 is an advantage for public health. These kinds of tests help treatment decisions because it is important to know that the patient does not have influenza or another disease that might require a specific treatment. It is also important in a hospital for preventing infections because doctors take patients with one particular virus and keep them apart from patients infected with other infectious agents."

"There are a range of D68 viruses, and our assay was designed to detect them all," said Dr. Storch. "We received many samples of enterovirus from other hospitals and ran the test blindly on all of them. In the viruses we looked at, the test worked 100% of the time. It only detected EV-D68 strains, and it did detect all of them; the test did not detect any of the other enteroviruses or rhinoviruses."

Details of the EV-D68 assay were published in the June 10, 2015, online edition of the Journal of Clinical Microbiology.

Related Links:
Washington University School of Medicine
Applied Biosystems


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Human Estradiol Assay
Human Estradiol CLIA Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more